BLA 761286 · Ucb INC
Rystiggo
Rozanolixizumab-Noli · Subcutaneous · Neonatal Fc Receptor Blocker
NovelPriority reviewOrphanCDER novel approval, Jun 26, 2023: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive
Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jun 26, 2023
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
22
12 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Rozanolixizumab" as an intervention, any sponsor and status, largest first.
- A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisPivotal-lookingCompleted
NCT03971422 · 200 participants · Start Jun 3, 2019 · Primary completion Aug 31, 2021
Drug: Rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 112 sites in all
- A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisPivotal-lookingCompleted
NCT04650854 · 165 participants · Start Feb 3, 2021 · Primary completion Jan 25, 2024
Drug: Rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Orange, California; San Francisco, California; Miami, Florida · 69 sites in all
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisPivotal-lookingRecruiting
NCT07463521 · 120 participants (planned) · Start May 27, 2026 · Primary completion Dec 1, 2028
Drug: Rozanolixizumab; Placebo · For: Ocular Myasthenia Gravis
Sites: Scottsdale, Arizona; O'Fallon, Illinois; Amherst, New York · 36 sites in all
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Pivotal-lookingActive, not recruiting
NCT05063162 · 113 participants · Start Feb 2, 2022 · Primary completion May 6, 2027
Drug: Rozanolixizumab · For: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Sites: Scottsdale, Arizona; Palo Alto, California; Aurora, Colorado · 55 sites in all
- A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisPivotal-lookingRecruiting
NCT07465289 · 100 participants (planned) · Start Sep 16, 2026 · Primary completion Mar 17, 2031
Drug: Rozanolixizumab · For: Ocular Myasthenia Gravis
Sites: Scottsdale, Arizona; Columbus, Ohio; Beijing, China · 18 sites in all
- A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisPivotal-lookingCompleted
NCT04124965 · 71 participants · Start Oct 29, 2019 · Primary completion Sep 1, 2021
Drug: Rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 43 sites in all
NCT02718716 · 66 participants · Start Mar 2, 2016 · Primary completion Feb 4, 2019
Drug: UCB7665 · For: Thrombocytopenia
Sites: Adelaide, Australia; Pleven, Bulgaria; Sofia, Bulgaria · 29 sites in all
NCT03859219 · 65 participants · Start Mar 18, 2019 · Primary completion Apr 28, 2020
Drug: Rozanolixizumab; Placebo · For: Healthy-volunteers
Sites: London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rystiggo (Rozanolixizumab-Noli)
2024 spending
$56.3M
Beneficiaries
279
1,363 claims
Per beneficiary
$201,820
$3,016.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $5,879,200 |
| 2024 | $56,307,919 |
Part B: Rystiggo (Rozanolixizumab-Noli) · HCPCS J9333
2024 spending
$30.7M
Beneficiaries
191
2,104 claims
Per beneficiary
$160,482
2024 ASP limit $22.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $30,652,022 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, et al. · Lancet Neurol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Saccà F, Pane C, Espinosa PE, et al. · Eur J Neurol 2023 · Systematic Review, Network Meta-Analysis
- Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.
Bril V, Drużdż A, Grosskreutz J, et al. · J Neuromuscul Dis 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.
Habib AA, Drużdż A, Grosskreutz J, et al. · J Neuromuscul Dis 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.
Ma Y, Nie X, Zhu G, et al. · CNS Drugs 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and metaߛanalysis.
Akhtar M, Akhtar M, Farooqi HA, et al. · Clin Neurol Neurosurg 2025 · Systematic Review, Meta-Analysis
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.